CSL's (ASX:CSL) fiscal first-half adjusted net profit after tax (NPAT) of $2.07 billion fell 4% below estimates by Visible Alpha of $2.16 billion, The Australian reported Tuesday, citing investment bank Barrenjoey.

The company's full fiscal year adjusted NPAT guidance of $3.11 billion to $3.21 billion, including a $90 million "headwind," is 3% below Visible Alpha's estimates of $3.26 billion, per the report.

Barrenjoey noted that CSL's Vifor and Behring divisions reported revenue 4% and 1% above estimates, respectively.

However, its Seqirus division's revenue fell 15% below market estimates due to declining vaccination rates, changing immunization settings, and increased competitive pressures, the investment firm added.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)